Literature DB >> 33536026

Hsa_circ_0025202 suppresses cell tumorigenesis and tamoxifen resistance via miR-197-3p/HIPK3 axis in breast cancer.

Hongjuan Li1, Qing Li1, Shan He2.   

Abstract

BACKGROUND: The involvement of circular RNAs (circRNAs) in tamoxifen (TAM) resistance has been identified. Herein, we aimed to identify the role and novel mechanisms of hsa_circ_0025202 in tamoxifen resistance in breast cancer (BC).
METHODS: The levels of hsa_circ_0025202, microRNA (miR)-197-3p, and homeodomain-interacting protein kinase 3 (HIPK3) were tested using quantitative real-time polymerase chain reaction and western blot. IC50 value of TAM, cell proliferation, cell cycle, cell invasion, migration, apoptosis, western blot, and mouse xenograft assays was used to demonstrate the effects of hsa_circ_0025202, miR-197-3p, and HIPK3 on BC cell tumorigenesis and TAM resistance. Dual-luciferase report and RNA immunoprecipitation assays were applied to explore the potential interaction between miR-197-3p and hsa_circ_0025202 or HIPK3.
RESULTS: Hsa_circ_0025202 was decreased in BC tissues and TAM resistant BC cells, and knockdown of hsa_circ_0025202 elevated the IC50 value of cells to TAM, led to the promotion of cell proliferation, invasion and migration, mediated cell cycle progression, and inhibited cell apoptosis in BC in vitro. Besides, the upregulation of hsa_circ_0025202 hindered tumor growth and promoted TAM sensitivity in vivo. In a mechanical study, hsa_circ_0025202 targeted miR-197-3p, and silencing of miR-197-3p reversed the regulatory effects of hsa_circ_0025202 knockdown on TAM resistance and malignant phenotypes. Additionally, HIPK3 was a target of miR-197-3p, and miR-197-3p overexpression enhanced TAM resistance and promoted cell malignant biological behaviors in BC by targeting HIPK3.
CONCLUSION: Hsa_circ_0025202 repressed cell tumorigenesis and TAM resistance via miR-197-3p/HIPK3 axis in BC, suggesting a potential therapeutic strategy to overcome chemoresistance in BC patients.

Entities:  

Keywords:  HIPK3; Hongjuan Li and Qing Li contributed equally to this study; Tamoxifen; hsa_circ_0025202; miR-197-3p

Mesh:

Substances:

Year:  2021        PMID: 33536026      PMCID: PMC7860040          DOI: 10.1186/s12957-021-02149-x

Source DB:  PubMed          Journal:  World J Surg Oncol        ISSN: 1477-7819            Impact factor:   2.754


  28 in total

1.  Cancer statistics, 2019.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2019-01-08       Impact factor: 508.702

2.  circRNA_0025202 Regulates Tamoxifen Sensitivity and Tumor Progression via Regulating the miR-182-5p/FOXO3a Axis in Breast Cancer.

Authors:  Yuting Sang; Bing Chen; Xiaojin Song; Yaming Li; Yiran Liang; Dianwen Han; Ning Zhang; Hanwen Zhang; Ying Liu; Tong Chen; Chen Li; Lijuan Wang; Wenjing Zhao; Qifeng Yang
Journal:  Mol Ther       Date:  2019-05-17       Impact factor: 11.454

Review 3.  Tamoxifen a pioneering drug: An update on the therapeutic potential of tamoxifen derivatives.

Authors:  Irshad Ahmad
Journal:  Eur J Med Chem       Date:  2017-11-24       Impact factor: 6.514

4.  Circular RNAs are a large class of animal RNAs with regulatory potency.

Authors:  Sebastian Memczak; Marvin Jens; Antigoni Elefsinioti; Francesca Torti; Janna Krueger; Agnieszka Rybak; Luisa Maier; Sebastian D Mackowiak; Lea H Gregersen; Mathias Munschauer; Alexander Loewer; Ulrike Ziebold; Markus Landthaler; Christine Kocks; Ferdinand le Noble; Nikolaus Rajewsky
Journal:  Nature       Date:  2013-02-27       Impact factor: 49.962

Review 5.  Breast Cancer: Current Molecular Therapeutic Targets and New Players.

Authors:  Siddavaram Nagini
Journal:  Anticancer Agents Med Chem       Date:  2017       Impact factor: 2.505

Review 6.  Selective estrogen-receptor modulators and antihormonal resistance in breast cancer.

Authors:  V Craig Jordan; Bert W O'Malley
Journal:  J Clin Oncol       Date:  2007-09-24       Impact factor: 44.544

7.  circKDM4C suppresses tumor progression and attenuates doxorubicin resistance by regulating miR-548p/PBLD axis in breast cancer.

Authors:  Yiran Liang; Xiaojin Song; Yaming Li; Peng Su; Dianwen Han; Tingting Ma; Renbo Guo; Bing Chen; Wenjing Zhao; Yuting Sang; Ning Zhang; Xiaoyan Li; Hanwen Zhang; Ying Liu; Yi Duan; Lijuan Wang; Qifeng Yang
Journal:  Oncogene       Date:  2019-08-12       Impact factor: 9.867

8.  Sox2 promotes tamoxifen resistance in breast cancer cells.

Authors:  Marco Piva; Giacomo Domenici; Oihana Iriondo; Miriam Rábano; Bruno M Simões; Valentine Comaills; Inmaculada Barredo; Jose A López-Ruiz; Ignacio Zabalza; Robert Kypta; Maria d M Vivanco
Journal:  EMBO Mol Med       Date:  2014-01       Impact factor: 12.137

Review 9.  CircRNAs in cancer metabolism: a review.

Authors:  Tao Yu; Yanfen Wang; Yu Fan; Na Fang; Tongshan Wang; Tongpeng Xu; Yongqian Shu
Journal:  J Hematol Oncol       Date:  2019-09-04       Impact factor: 17.388

10.  Targeting the circBMPR2/miR-553/USP4 Axis as a Potent Therapeutic Approach for Breast Cancer.

Authors:  Yiran Liang; Xiaojin Song; Yaming Li; Tingting Ma; Peng Su; Renbo Guo; Bing Chen; Hanwen Zhang; Yuting Sang; Ying Liu; Yi Duan; Ning Zhang; Xiaoyan Li; Wenjing Zhao; Lijuan Wang; Qifeng Yang
Journal:  Mol Ther Nucleic Acids       Date:  2019-05-22
View more
  7 in total

1.  YY1 as a promoter regulating the circ_0001946/miR-671-5p/EGFR axis to promote chemotherapy resistance in breast cancer cells.

Authors:  Ge Gao; Xiaoyan Li; Jiabeini Zhang; Hong Yu
Journal:  Am J Transl Res       Date:  2022-04-15       Impact factor: 3.940

Review 2.  Advances in the Study of CircRNAs in Tumor Drug Resistance.

Authors:  Song Wang; Long Qian; Tingting Cao; Li Xu; Yan Jin; Hao Hu; Qingsheng Fu; Qian Li; Ye Wang; Jiawei Wang; Yabin Xia; Xiaoxu Huang
Journal:  Front Oncol       Date:  2022-05-09       Impact factor: 5.738

3.  Expression levels and clinical values of miR-92b-3p in breast cancer.

Authors:  Yu Du; Zhuang Miao; Kedi Wang; Yan Lv; Lijuan Qiu; Lusheng Guo
Journal:  World J Surg Oncol       Date:  2021-08-11       Impact factor: 2.754

Review 4.  The Role of Circular RNAs in the Drug Resistance of Cancers.

Authors:  Xin-Yuan Liu; Qi Zhang; Jing Guo; Peng Zhang; Hua Liu; Zi-Bin Tian; Cui-Ping Zhang; Xiao-Yu Li
Journal:  Front Oncol       Date:  2022-01-05       Impact factor: 6.244

Review 5.  MALAT1-miRNAs network regulate thymidylate synthase and affect 5FU-based chemotherapy.

Authors:  Janusz Matuszyk
Journal:  Mol Med       Date:  2022-08-03       Impact factor: 6.376

Review 6.  Non-coding RNA in cancer drug resistance: Underlying mechanisms and clinical applications.

Authors:  Xuehao Zhou; Xiang Ao; Zhaojun Jia; Yiwen Li; Shouxiang Kuang; Chengcheng Du; Jinyu Zhang; Jianxun Wang; Ying Liu
Journal:  Front Oncol       Date:  2022-08-17       Impact factor: 5.738

Review 7.  The role of CircRNA/miRNA/mRNA axis in breast cancer drug resistance.

Authors:  Mohammad H Ghazimoradi; Sadegh Babashah
Journal:  Front Oncol       Date:  2022-09-05       Impact factor: 5.738

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.